Vol. 9, Special Issue 7 (2020)
Assessment of conception rate and number of artificial insemination required for pregnancy in artificially induced crossbred repeat breeder animals by using reserpine and dexamethasone
K Nagaraja, Jagadeesh S Sanganal, SM Byregowda, NB Shridhar, U Sunilchandra, A Murugeppa, ML Satyanarayana and V Chandrashekaramurthy
The artificial induction of lactation were carried out in 30 animals, divided into three groups with 10 animals in each group. Group I, animals which were in first lactation served as control, not given any treatment. Group II, administered with 17β-estradiol at 0.1 mg/kg body weight and progesterone at 0.25 mg/kg body weight were administered from day 1 to 7 twice daily 12 h apart by subcutaneous route at either side neck region on alternate days. Dexamethasone (20mg/animal/day) was administered for 4 days (day 14 to 17) by intramuscular route. The treatment schedule for Group III, from day 1 to 7 were adopted same as group II and reserpine (5 mg/animal/day) were administered for 4 days from day 8 to 14 on alternate days (i.e., day 8, 10, 12 and 14) by intramuscular route. All the animals exhibited estrous between 30 to 35 from the day of milking and were inseminated when they exhibited first estrous cycle after lactation induction. The percentage of conception rate obtained was 50% (10/10), 40% (4/10), and 50% (5/10) in group I, II and III respectively. The current study in group I and III 5 out of 10 (50%) animals were confirmed pregnant. In group II conception rate was 40% where in 4 out of 10 animals were confirmed pregnant Also the number of inseminations taken for the animal to became pregnant in group I was minimum as ≤3 compared to group II and III which was ≥ 4.
How to cite this article:
K Nagaraja, Jagadeesh S Sanganal, SM Byregowda, NB Shridhar, U Sunilchandra, A Murugeppa, ML Satyanarayana and V Chandrashekaramurthy. Assessment of conception rate and number of artificial insemination required for pregnancy in artificially induced crossbred repeat breeder animals by using reserpine and dexamethasone. The Pharma Innovation Journal. 2020; 9(7S): 132-135.